Amneal Pharmaceuticals (AMRX) announced the FDA has approved the company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of Restasis 0.05%, a registered trademark of Allergan, an AbbVie (ABBV) company.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces FDA approval for iohexol injection
- Amneal Pharmaceuticals Reports Strong Q3 Growth Amid Challenges
- Amneal Pharmaceuticals price target raised to $13 from $11 at Piper Sandler
- Amneal Pharmaceuticals Reports Strong Q3 2025 Results
- Amneal Pharmaceuticals reports Q3 adjusted EPS 17c, consensus 14c